Dr. Plotkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St Yaw 9
Brain Tumor Center Neuro-Oncology
Boston, MA 02114Phone+1 617-724-8770Fax+1 617-724-8769- Is this information wrong?
Education & Training
- Massachusetts General HospitalFellowship, Neuro-Oncology, 2002 - 2003
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1999 - 2002
- Tulane UniversityInternship, Internal Medicine, 1998 - 1999
- Tulane University School of MedicineClass of 1998
Certifications & Licensure
- NH State Medical License 2023 - 2025
- MA State Medical License 2002 - 2025
- LA State Medical License 2002 - 2002
- American Board of Psychiatry and Neurology Neurology
- United council of neurological subspecialtiesNeuro-Oncology
Clinical Trials
- Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Start of enrollment: 2008 Mar 01
- Concentration and Activity of Lapatinib in Vestibular Schwannomas Start of enrollment: 2009 Jun 01
- Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.Fertitta, L., Bergqvist, C., Sarin, K., Plotkin, S., Moertel, C., Petersen, A., Cannon, A., Berman, Y., Pichard, D., Röhl, C., Lessing, A., Brizion, B., Peiffer, B., R...> ;The British Journal of Dermatology. 2024 Jan 23
- Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.Funk, M., Sakamoto, F., Ly, I., Muzikansky, A., Roberts, J., Farinelli, W., Anderson, R., Richey, P., Plotkin, S., Jordan, J., Levin, Y., Garibyan, L., Blakeley, J.> ;Journal of the American Academy of Dermatology. 2023 Dec 10
- Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.Verena Staedtke, Kara Anstett, David Bedwell, Marco Giovannini, Kim Keeling, Robert Kesterson, YooRi Kim, Bruce Korf, André Leier, Miranda L McManus, Herb Sarnoff, Jer...> ;Clinical Trials. 2024 Feb 1
- Join now to see all
Journal Articles
- Increasing Access to Specialty Care for Rare Diseases: A Case Study Using a Foundation Sponsored Clinic Network for Patients with Neurofibromatosis 1, Neurofibromatosi...Scott R Plotkin, Justin T Jordan, BioMed Central
Press Mentions
- University of Miami Miller School of Medicine Selected for National NF2 Tumor Clinical TrialJune 1st, 2022
- Wayne Biopharma Firm Targeting Rare Genetic Disorders Raises $6MMay 1st, 2020
- Antiangiogenesis Treatment Improves Hearing in Some NF2 PatientsJuly 8th, 2009
- Join now to see all
Grant Support
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1995–1997
- Fetal Alcohol Effects On Blood Brain Barrier TransportNational Institute On Alcohol Abuse And Alcoholism1994
Professional Memberships
- Member
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Industry Relationships
- Co-Founder, NF2 Therapeutics
- Co-Founder, NFlection Therapeutics
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: